Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960 · View on ClinicalTrials.gov ↗
Study Summary
Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Conditions Studied
Interventions
- DEVICE CereVasc eShunt System
- DEVICE VP Shunt
Study Locations (20)
New York
- Albany Medical Center — Albany
- University at Buffalo Neurosurgery — Buffalo
- Northwell Health — Manhasset
- NYU Langone Health — New York
- Icahn School of Medicine at Mount Sinai — New York
- Lenox Hill Hospital — New York
Massachusetts
- Massachusetts General Hospital — Boston
- Brigham and Women's Hospital — Boston
- Beth Israel Deaconess Medical Center — Boston
Florida
- Baptist Medical Center - Jacksonville — Jacksonville
- University of South Florida — Tampa
Illinois
- Northwestern University — Chicago
- Advocate Lutheran General Hospital — Park Ridge
California
- University of Southern California — Los Angeles
Connecticut
- Yale University — New Haven
Indiana
- Indiana University — Indianapolis
Kansas
- University of Kansas Medical Center — Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2031-06 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06498960
The ClinicalTrials.gov registry entry for NCT06498960 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CereVasc, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Normal Pressure Hydrocephalus appearing as the primary indexed condition, and to 2 interventions — of which CereVasc eShunt System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06498960 reports 20 study locations spanning 11 distinct geographic areas — top geographies include New York, Massachusetts, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06498960 about?
NCT06498960 is a clinical study titled "Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus". Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
What is the current status of trial NCT06498960?
This trial is currently recruiting. It is a NA study. The enrollment target is 230 participants. The study started on 2024-11-26. Estimated completion is 2031-06.
What conditions does trial NCT06498960 study?
This clinical trial studies the following conditions: Normal Pressure Hydrocephalus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06498960?
The interventions under investigation include: CereVasc eShunt System (DEVICE), VP Shunt (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06498960?
This trial is sponsored by CereVasc, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06498960 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.